09.30.16
PCI Pharma Services will bring its expertize to the stage at CPHI with two speakers at the ICSE Exhibitor Showcase. On October 4 at 1:30pm David O’Connell, director of pharmaceutical development, PCI Pharma Services, will present the first of the two topics, outlining the key elements for the safe handling and manufacture of solid dose potent molecules. The session will advise on the complexities of safe processing of highly potent products and key considerations when choosing an outsourcing partner including regulatory requirements.
“The pharmaceutical landscape continues to evolve with R&D pipelines developing new chemical entities for a wide range of disease states,” said Mr. O’Connell. “The market has seen a shift towards more specialist medicines such as oncological and neurological products, in turn leading to an increase in the number of potent compounds requiring expert management. With the complexities involved in the management of potent molecules and the regulatory requirements to ensure safe handling, it is imperative to use the right partner for successful development and manufacturing.”
The second speaker topic will be presented by Ian Parsonage, senior director of global serialization, PCI Pharma Services on October 5 at 12:00 noon, covering key considerations, lessons learned and best practices for global serialization strategy and implementation.
“With drug counterfeiting on the rise globally and regulatory deadlines fast approaching, the pharmaceutical supply chain will soon be at critical point to ensure patient safety,” said Mr. Parsonage. “From drug manufacturers to distributors, supply chain partners need to make crucial decisions to upgrade production lines in compliance with traceability deadlines. I’m looking forward to sharing insights and best practices on how to execute a serialization strategy at the event.”
Visit PCI during the show at booth 3B16.
“The pharmaceutical landscape continues to evolve with R&D pipelines developing new chemical entities for a wide range of disease states,” said Mr. O’Connell. “The market has seen a shift towards more specialist medicines such as oncological and neurological products, in turn leading to an increase in the number of potent compounds requiring expert management. With the complexities involved in the management of potent molecules and the regulatory requirements to ensure safe handling, it is imperative to use the right partner for successful development and manufacturing.”
The second speaker topic will be presented by Ian Parsonage, senior director of global serialization, PCI Pharma Services on October 5 at 12:00 noon, covering key considerations, lessons learned and best practices for global serialization strategy and implementation.
“With drug counterfeiting on the rise globally and regulatory deadlines fast approaching, the pharmaceutical supply chain will soon be at critical point to ensure patient safety,” said Mr. Parsonage. “From drug manufacturers to distributors, supply chain partners need to make crucial decisions to upgrade production lines in compliance with traceability deadlines. I’m looking forward to sharing insights and best practices on how to execute a serialization strategy at the event.”
Visit PCI during the show at booth 3B16.